CULLINAN THERAPEUTICS, INC. (CGEM) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2025-12-31..
Dividend safety
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -219.88M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2025-12-31 | (m) | $-219.88M | (m) |
| 2025-09-30 | (m) | $-216.81M | (m) |
| 2025-06-30 | (m) | $-206.76M | (m) |
| 2025-03-31 | (m) | $-178.74M | (m) |
| 2024-12-31 | (m) | $-167.38M | (m) |
| 2024-09-30 | (m) | $-143.54M | (m) |
| 2024-06-30 | (m) | $-142.16M | (m) |
| 2024-03-31 | (m) | $-132.35M | (m) |
| 2023-12-31 | (m) | $-153.16M | (m) |
| 2023-09-30 | (m) | $-156.14M | (m) |
| 2023-06-30 | (m) | $-141.76M | (m) |
| 2023-03-31 | (m) | $65.35M | (m) |
| 2022-12-31 | (m) | $111.21M | (m) |
| 2022-09-30 | (m) | $105.48M | (m) |
| 2022-06-30 | (m) | $112.94M | (m) |
| 2022-03-31 | (m) | $-77.60M | (m) |
| 2021-12-31 | (m) | $-65.57M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-51.80M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |